Last reviewed · How we verify
Placebo(for Rosuvastatin 20mg) — Competitive Intelligence Brief
phase 3
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo(for Rosuvastatin 20mg) (Placebo(for Rosuvastatin 20mg)) — IlDong Pharmaceutical Co Ltd. Placebo is an inert substance with no active pharmacological mechanism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo(for Rosuvastatin 20mg) TARGET | Placebo(for Rosuvastatin 20mg) | IlDong Pharmaceutical Co Ltd | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo(for Rosuvastatin 20mg) CI watch — RSS
- Placebo(for Rosuvastatin 20mg) CI watch — Atom
- Placebo(for Rosuvastatin 20mg) CI watch — JSON
- Placebo(for Rosuvastatin 20mg) alone — RSS
Cite this brief
Drug Landscape (2026). Placebo(for Rosuvastatin 20mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-rosuvastatin-20mg. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab